Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-week extension study of BGF MDI (PT010), GFF MDI (PT003), and BFF MDI (PT009) vs Symbicort Turbuhaler in Japanese COPD
jRCT2080224021Phase 3
- Sponsor
- Pearl Therapeutics
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BGF MDI HFO, fluticasone propionate + formoterol fumarate + glycopyrronium bromide, budesonide + formoterol fumarate and budesonide in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics.
02
Drugs
BGF MDI HFOfluticasone propionate + formoterol fumarate + glycopyrronium bromidebudesonide + formoterol fumaratebudesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224021.